Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
427 Approval timings and review speed of immune checkpoint inhibitors (ICIs) in cancer therapy between the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) from 2010-2022
Compose a Response to This Article
Other responses
No responses have been published for this article.